---
title: "C4 Therapeutics, Inc. (CCCC.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/CCCC.US.md"
symbol: "CCCC.US"
name: "C4 Therapeutics, Inc."
industry: "Biotechnology"
datetime: "2026-05-19T21:36:06.253Z"
locales:
  - [en](https://longbridge.com/en/quote/CCCC.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/CCCC.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/CCCC.US.md)
---

# C4 Therapeutics, Inc. (CCCC.US)

## Company Overview

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1. The company is also developing oncology product candidate, CFT8919, an orally bioavailable, allosteric, mutant-selective bidac degrader of epidermal growth factor receptor, with an L858R mutation in non-small cell lung cancer; and new degraders focused on inflammation, neuroinflammation, and neurodegeneration. It has strategic collaborations F.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.c4therapeutics.com](https://www.c4therapeutics.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-19T04:30:14.000Z

**Overall: D (0.63)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 247 / 386 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -12.37% |  |
| Net Profit YoY | -0.51% |  |
| P/B Ratio | 1.51 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 354782298.36 |  |
| Revenue | 34861000.00 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -48.35% | E |
| Profit Margin | -297.76% | E |
| Gross Margin | 100.00% | A |
| Revenue YoY | -12.37% | E |
| Net Profit YoY | -0.51% | C |
| Total Assets YoY | 2.92% | C |
| Net Assets YoY | 20.04% | A |
| Cash Flow Margin | 91.86% | C |
| OCF YoY | -12.37% | E |
| Turnover | 0.11 | E |
| Gearing Ratio | 28.77% | B |

```chart-data:radar
{
  "title": "Longbridge Financial Score - C4 Therapeutics, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-12.37%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-0.51%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "1.51",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "354782298.36",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "34861000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-48.35%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-297.76%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "100.00%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "-12.37%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "-0.51%",
          "rating": "C"
        },
        {
          "name": "Total Assets YoY",
          "value": "2.92%",
          "rating": "C"
        },
        {
          "name": "Net Assets YoY",
          "value": "20.04%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "91.86%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "-12.37%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "0.11",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "28.77%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -3.42 | 314/386 | - | - | - |
| PB | 1.51 | 139/386 | 1.37 | 1.09 | 0.81 |
| PS (TTM) | 10.18 | 163/386 | 7.82 | 6.44 | 4.03 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-13T04:00:00.000Z

Total Analysts: **8**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 7 | 88% |
| Overweight | 1 | 13% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 3.11 |
| Highest Target | 30.00 |
| Lowest Target | 6.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/CCCC.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/CCCC.US/norm.md)
- [Related News](https://longbridge.com/en/quote/CCCC.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/CCCC.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**